利伐沙班片能长期吃吗

(Rivaroxaban) is a new oral anticoagulant that can directly and selectively bind to FXa to inhibit the conversion of prothrombin into thrombin, thereby exerting an anti-thrombotic effect. Compared with the traditional anticoagulant drug vitamin antagonist, rivaroxaban is mainly excreted through the biliary tract and kidneys, so it is not easily affected by diet and drugs. At the same time, rivaroxaban has a quick onset of action, high oral bioavailability, and is safer and more convenient. Based on the above characteristics, higher doses (10-20 mg once daily) of rivaroxaban have been widely used in the prevention and treatment of various thromboembolic diseases.

So, many patients must have asked, can rivaroxaban tablets be taken for a long time?

Generally speaking, as long as the patient is not allergic to any ingredients in Rivaroxaban tablets, can continue to benefit from it, and tolerates the drug without any toxic reactions, in principle, it can be taken for a long time. Of course, if some uncontrollable factors occur during this period, the patient needs to consider whether to continue taking the medication based on the doctor's advice.

The recommended dose of rivaroxaban (i.e. Xarelto) is 10 mg/time orally, once/day. When the wound has stopped bleeding, the patient's first medication should be administered between 6 and 10 hours after surgery. In coadministration, rivaroxaban may increase rivaroxaban exposure when used concomitantly with strong inhibitors of CYP3A4 and P-gp.

Studies have shown that when rivaroxaban is used concurrently with strong inhibitors of CYP3A4 and P-gp, the plasma concentration of rivaroxaban will increase, so there is a risk of bleeding. Therefore, simultaneous use of rivaroxaban and strong inhibitors of CYP3A4 and P-gp should be avoided. Erythromycin, clarithromycin, and fluconazole have moderate effects on rivaroxaban exposure and should be used with caution. Coadministration of rivaroxaban with the strong CYP3A4 inducer rifampicin will also lead to decreased plasma concentrations, and caution should be exercised when coadministered with strong CYP3A4 inducers.

Recommended hot articles: /newsDetail/73226.html